×
GSK Inventory 2010-2024 | GSK
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
GSK inventory for the quarter ending September 30, 2024 was
$7.697B
, a
10.95% increase
year-over-year.
GSK inventory for 2023 was
$6.839B
, a
7.44% increase
from 2022.
GSK inventory for 2022 was
$6.365B
, a
19.96% decline
from 2021.
GSK inventory for 2021 was
$7.952B
, a
3.29% increase
from 2020.
View More
GSK Inventory 2010-2024 | GSK
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
GSK inventory for 2023 was
$6.839B
, a
7.44% increase
from 2022.
GSK inventory for 2022 was
$6.365B
, a
19.96% decline
from 2021.
GSK inventory for 2021 was
$7.952B
, a
3.29% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$158.3B
Bristol Myers Squibb (BMY)
$119.4B
Vertex Pharmaceuticals (VRTX)
$116.1B
Gilead Sciences (GILD)
$112.4B
CSL (CSLLY)
$87.2B
Regeneron Pharmaceuticals (REGN)
$81.1B
Argenex SE (ARGX)
$36.6B
Alnylam Pharmaceuticals (ALNY)
$31.6B
BioNTech SE (BNTX)
$27.1B
Biogen (BIIB)
$23B
Illumina (ILMN)
$22.2B
BeiGene (BGNE)
$18.6B
Moderna (MRNA)
$15.8B
Incyte (INCY)
$13.8B
Genmab (GMAB)
$13.7B
Insmed (INSM)
$13.1B
BioMarin Pharmaceutical (BMRN)
$12.2B
Bio-Techne Corp (TECH)
$11.3B
Vaxcyte (PCVX)
$11B
Sarepta Therapeutics (SRPT)
$10.9B
Exelixis (EXEL)
$10.2B
Exact Sciences (EXAS)
$9.8B
QIAGEN (QGEN)
$9.8B
Revolution Medicines (RVMD)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$9.1B
Intra-Cellular Therapies (ITCI)
$9.1B
Repligen (RGEN)
$8B
Ascendis Pharma (ASND)
$7.9B
Jazz Pharmaceuticals (JAZZ)
$7.7B